GelSana, an Innosphere Ventures client company, today announced that Diana Verrilli, Chief Growth Officer at DispatchHealth, will join the Company’s Board of Directors. Diana, an accomplished healthcare leader brings extensive experience in commercialization and business strategy planning and execution.

“GelSana is very fortunate to have Diana join our Board,” said Melissa Krebs, CEO and Founder of GelSana. “As we prepare to launch our first product Cleragel™ in 2025 and kick off our Series A financing, Diana’s strategic background and expertise in launching new products will be invaluable in support of our growth.”

Prior to joining DispatchHealth, Diana was at McKesson for 23 years holding multiple roles culminating in Senior Vice President, Corporate Strategy and Business Development. She has executed organizational vision, steered complex operations, and provided strategic insight to expand healthcare accessibility, create scale, and achieve growth. Her expertise includes development and execution of high-impact marketing and sales initiatives to drive revenue growth.

“I am delighted to be joining the GelSana’s Board of Directors at this pivotal moment in the Company’s journey,” said Diana Verrilli. “GelSana’s wound healing polymers offer ground-breaking solutions to all wound types including challenging wounds such as diabetic ulcers and burns. These polymers are unique in their properties including their potential to evade the foreign body response, reduce pain and promote healing. These products have the potential to improve patient outcomes and comfort during healing.”

About GelSana

GelSana is developing ground-breaking polymers that offer enhanced wound healing and handling characteristics differentiated from other would dressings available today. GelSana’s patented polymers creates an anti-inflammatory environment reducing the need for repeated applications and making wound care more efficient and cost-effective. GelSana’s first product, Cleragel™, will be commercially available in 2025.

For more information visit gelsanatherapeutics.com